| Texto completo | |
| Autor(es): |
Santos, Diego D.
;
Sasso, Gisela R. S.
;
Belote, Nycole M.
;
da Silva, Rafael Andre
;
Lice, Izabella
;
Correia-Silva, Rebeca D.
;
Borges, Fernanda T.
;
Carbonel, Adriana A. F.
;
Gil, Cristiane D.
Número total de Autores: 9
|
| Tipo de documento: | Artigo Científico |
| Fonte: | Life Sciences; v. 318, p. 10-pg., 2023-02-17. |
| Resumo | |
Aims: Evaluate the role of galectin-3 in the liver using an acute model of cisplatin-induced toxicity. Material and methods: Modified citrus pectin (MCP) treatment was used to inhibit galectin-3. Rats were distrib-uted into four groups: SHAM, CIS, MCP and MCP + CIS. On days 1-7, animals were treated by oral gavage with 100 mg/kg/day of MCP (MCP and MCP + CIS groups). On days 8, 9 and 10, animals received intraperitoneal injection of 10 mg/kg/day of cisplatin (CIS and MCP + CIS groups) or saline (SHAM and MCP groups). Key findings: Cisplatin administration caused a marked increase in hepatic leukocyte influx and liver degenera-tion, and promoted reactive oxygen species production and STAT3 activation in hepatocytes. Plasma levels of cytokines (IL-6, IL-10), and hepatic toxicity biomarkers (hepatic arginase 1, alpha-glutathione S-transferase, sorbitol dehydrogenase) were also elevated. Decreased galectin-3 levels in the livers of animals in the MCP + CIS group were also associated with increased hepatic levels of malondialdehyde and mitochondrial respiratory complex I. Animals in the MCP + CIS group also exhibited increased plasma levels of IL-1 beta, TNF-alpha, and aspartate trans-aminase 1. Furthermore, MCP therapy efficiently antagonized hepatic galectin-9 in liver, but not galectin-1, the latter of which was increased. Significance: Reduction of the endogenous levels of galectin-3 in hepatocytes favors the process of cell death and increases oxidative stress in the acute model of cisplatin-induced toxicity. (AU) | |
| Processo FAPESP: | 20/03565-2 - Efeito da anexina A1 e de seus peptídeos miméticos em modelos de resposta inflamatória in vitro (2D e 3D) e de toxicidade aguda in vivo |
| Beneficiário: | Cristiane Damas Gil |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |